Journal Article

Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial

Kyeremanteng, Kwadwo, Prosperi-Porta, Graeme, Koopman, Zandra, Robinson, Lisa, Goodliffe, Laura, Amin, Faizan, Lepage-Ratte, Melissa Fay, Ainsworth, Craig, Jung, Richard G., Simard, Trevor, Santo, Pietro Di, Morgan, Baylie, Feagan, Hannah, Belley-Cote, Emilie P., Parlow, Simon, Fernando, Shannon M., Marbach, Jeffrey A., Wells, George A., Mathew, Rebecca, Sterling, Lee H., Hibbert, Benjamin, Motazedian, Pouya, Labinaz, Marino

2023

Overview

Cardiogenic shock (CS) is a state of end-organ hypoperfusion related to cardiac dysfunction. Current guidelines recommend consideration of inotrope therapy in patients with CS, however no robust data support their use. The purpose of the CAPITAL DOREMI2 trial is to examine the efficacy and safety of inotrope therapy against placebo in the initial resuscitation of patients with CS. This is a multi-center, double-blind, randomized, placebo-controlled trial comparing single-agent inotrope therapy to placebo in patients with CS. A total of 346 participants with Society for Cardiovascular Angiography and Interventions class C or D CS will be randomized in a 1:1 fashion to inotrope or placebo therapy, which will be administered over a 12-hour period. After this period, participants will continue open-label therapies at the discretion of the treating team. The primary outcome is a composite of all-cause in-hospital death, and, as measured during the 12-hour intervention period, any of: sustained hypotension or high dose vasopressor requirements, lactate greater than 3.5 mmol/L at 6 hours or thereafter, need for mechanical circulatory support, arrhythmia leading to emergent electrical cardioversion, and resuscitated cardiac arrest. All participants will be followed for the duration of their hospitalization, and secondary outcomes will be assessed at the time of discharge. This trial will be the first to establish the safety and efficacy of inotrope therapy against placebo in a population of patients with CS and has the potential to alter the standard care provided to this group of patients.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Angiography / Arrhythmia / Double-Blind Method / Drug dosages / Effectiveness / Heart Arrest - complications / Hemodynamics / Hospital Mortality / Humans / Hypotension / Informed consent / Intervention / Medical records / Mortality / Multicenter Studies as Topic / Patients / Placebos / Pulmonary arteries / Randomized Controlled Trials as Topic / Safety / Shock, Cardiogenic - drug therapy / Shock, Cardiogenic - therapy / Statistical analysis / Therapy / Treatment Outcome / Vasoconstrictor Agents - therapeutic use